ClinicalTrials.gg
CompletedNCT03899259BRAVE-AA2Updated Apr 7, 2026Results posted

A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

A Phase 3 interventional study of Baricitinib and Placebo in Alopecia Areata, sponsored by Eli Lilly and Company. Completed at 96 sites in 10 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
606
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies in Alopecia Areata with a site in United States — 21 open to participants now, 32 under way, 8 of them phase 3. Alopecia Areata · United States.

Enrollment
8th of 84
606 · median 46
Started
2019
with 5 others
Phase 3
12 of 98
6 open now
Registered
45th of 98
by date
Lead sponsor
3 of 98
Eli Lilly and Company

Among the 98 studies in Alopecia Areata with a site in United States, this one is the 8th largest by enrollment of the 84 interventional ones that give a count, is one of 6 that started in 2019, is one of 12 in phase 3, and was the 45th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

21 of the 98 studies in Alopecia Areata with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Alopecia Areata with a site in United States, or all of them as a file.
02

Study summary

The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).

03

Conditions studied

  • Alopecia Areata

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are at least 18 years and ≤60 years for males (≤70 years of age for females) at the time of .
  • Have severe or very severe AA, as determined by all of the following:

    • Current AA episode of more than 6 months' duration and hair loss encompassing ≥50% of the scalp, as measured by SALT (AA-IGA of 3 or 4) at screening and baseline.
    • No spontaneous improvement over the past 6 months.
    • Current episode of severe or very severe AA of less than 8 years. Note: participants who have severe or very severe AA for ≥8 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years.
  • Male or nonpregnant, nonbreastfeeding female participants.

Exclusion criteria

Exclusion Criteria:

  • Primarily "diffuse" type of AA.
  • Are currently experiencing other forms of alopecia or any other concomitant conditions that would interfere with evaluations of the effect of study medication on AA.
  • Previously treated with an oral Janus kinase (JAK) inhibitor and had an inadequate response (for example, absence of significant terminal hair growth after at least 12 weeks of treatment).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
606 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received two placebo tablets matched to baricitinib, administered orally once daily (QD) to maintain the blind.

    Drug: Placebo

  • Experimental
    2 mg Baricitinib

    Participants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind.

    Drug: Baricitinib

  • Experimental
    4 mg Baricitinib

    Participants received one 4 mg Baricitinib tablet and one placebo tablet administered orally QD to maintain the blind.

    Drug: Baricitinib

  • Placebo comparator
    Placebo/ Placebo

    Participants who received two placebo tablets administered orally QD in Period 1 continue to receive the same placebo in Period 2.

    Drug: Placebo

  • Experimental
    Placebo/ 2-mg Baricitinib

    Participants who received two placebo at Period 1 switched to receive 2 mg Baricitinib dose administered orally QD in Period 2.

    Drug: Baricitinib

  • Experimental
    Placebo/ 4-mg Baricitinib

    Participants who received two placebo at Period 1 switched to receive 4 mg Baricitinib dose administered orally QD in Period 2.

    Drug: Baricitinib

  • Experimental
    2-mg Baricitinib/ 2-mg Baricitinib

    Participants who received 2 mg Baricitinib at Period 1 continued to receive same 2 mg Baricitinib dose administered orally QD in Period 2.

    Drug: Baricitinib

  • Experimental
    2-mg Baricitinib/ 4-mg Baricitinib

    Participants who received 2 mg Baricitinib at Period 1 switched to receive 4 mg Baricitinib dose administered orally QD in Period 2.

    Drug: Baricitinib

  • Experimental
    4-mg Baricitinib/ Placebo

    Participants who received 4 mg Baricitinib at Period 1 switched to receive Placebo administered orally QD in Period 2.

    Drug: Placebo

  • Experimental
    4-mg Baricitinib/ 2-mg Baricitinib

    Participants who received 4 mg Baricitinib at Period 1 switched to receive 2 mg Baricitinib administered orally QD in Period 2.

    Drug: Baricitinib

  • Experimental
    4-mg Baricitinib/ 4-mg Baricitinib

    Participants who received 4 mg Baricitinib at Period 1 continued to receive same 4 mg Baricitinib administered orally QD in Period 2.

    Drug: Baricitinib

Interventions

  • Administered orally

    Also known as: LY3009104

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20

    The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes.

    Time frame: Week 36

Secondary outcomes

  1. Percent Change From Baseline in SALT Score at Week 36

    SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes. Least Squares Mean (LSM) was calculated using analysis of covariance (ANCOVA) with geographic region duration of current episode at baseline (\< 4 years versus ≥4 years), treatment group, and baseline value in the model.

    Time frame: Baseline, Week 36

  2. Percentage of Participants Achieving 50% Improvement of Severity of Alopecia Tool (SALT50)

    SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes. SALT50 indicates at least a 50 % improvement from baseline in the SALT score.

    Time frame: Week 12

  3. Percentage of Participants With Patient-Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥2-point Improvement From Baseline Among Participants With a Score of ≥3 at Baseline

    PRO is an assessment of the particpant's current extent of scalp involvement. It is comprised of 5 category response options: 0= No missing hair (0% of my scalp is missing hair; I have a full head of hair); 1 = A limited area (1% to 20% of my scalp is missing hair); 2 = A moderate area (21% to 49% of my scalp is missing hair); 3 = A large area (50% to 94% of my scalp is missing hair); and 4 = Nearly all or all (95% to 100% of my scalp is missing hair).

    Time frame: Week 36

  4. Time for Participants to Achieve SALT ≤ 20 at Week 36.

    The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes. Kaplan-Meier method was used for analysis. Time for participants to achieve salt ≤ 20 at week 36 were reported in this outcome measure.

    Time frame: Week 36

  5. Percentage of Participants Achieving Clinician-Reported Outcome (ClinRO) Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥2 at Baseline)

    ClinRO is a clinician reported assessment which measures a participant's EB hair loss. It is comprised of 4 category response options: 0 = EB have full coverage and no areas of hair loss; 1 = There are minimal gaps in EB hair and distribution is even; 2 = There are significant gaps in EB hair or distribution is not even; 3 = No notable EB.

    Time frame: Week 36

  6. Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥2 at Baseline)

    ClinRO measure for EL hair loss is comprised of 4 category response options: 0 = The EL form a continuous line along the eyelids on both eyes; 1 = There are minimal gaps and the EL are evenly spaced along the eyelids on both eyes; 2 = There are significant gaps along the eyelids or the EL are not evenly spaced along the eyelids; 3 = No notable EL.

    Time frame: Week 36

  7. Percentage of Participants Achieving Patient-Reported Outcome (PRO) Measure for EB 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With PRO Measure for EB ≥2 at Baseline)

    PRO is an assessment of the participant's current appearance of eyebrows. It is comprised of 4 category response options: 0 = I have full EB on each eye; 1= I have a minimal gap(s) or a minimal amount of thinning in at least 1 of my EB; 2 = I have a large gap(s) or a large amount of thinning in at least 1 of my EB; and 3 = I have no or barely any EB hairs.

    Time frame: Week 36

  8. Percentage of Participants Achieving PRO Measure for EL 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With PRO Measure EL ≥2 at Baseline)

    PRO assessment of the participant's current appearance of EL. It is comprised of 4 category response options: 0 = I have full EL on each eyelid; 1 = I have a minimal gap or minimal gaps along the eyelids; 2 = I have a large gap or large gaps along the eyelids; and 3 = I have no or barely any EL hair.

    Time frame: Week 36

  9. Change From Baseline in Skindex-16 Alopecia Areata (AA) Symptoms Domain Score

    Skindex-16 AA was adapted from Skindex-16 for use among adults with alopecia areata. It examines the degree to which the participant is bothered by alopecia (hair loss) and associated symptoms. It is composed of 16 items grouped under 3 domains: Symptoms (4 items), Emotions (7 items), and Functioning (5 items). The score of each item ranges from 0 (never bothered) to 6 (always bothered). Symptoms domain score is sum of 4 items, range 0 to 24; Emotions domain score is sum of 7 items, range 0 to 42; Functioning score is sum of 5 items, range 0 to 30. Higher scores indicate a greater impact on quality of life. LS means was calculated using the ANCOVA model with geographic region, duration of current episode at Baseline (\<4 years vs. ≥ 4years), treatment group, and baseline value as fixed factors.

    Time frame: Baseline, Week 36

  10. Change From Baseline in Skindex-16 AA Emotions Domain Score at Week 36

    Skindex-16 AA was adapted from Skindex-16 for use among adults with alopecia areata. It examines the degree to which the participant is bothered by alopecia (hair loss) and associated symptoms. It is composed of 16 items grouped under 3 domains: Symptoms (4 items), Emotions (7 items), and Functioning (5 items). The score of each item ranges from 0 (never bothered) to 6 (always bothered). Symptoms domain score is sum of 4 items, range 0 to 24; Emotions domain score is sum of 7 items, range 0 to 42; Functioning score is sum of 5 items, range 0 to 30. Higher scores indicate a greater impact on quality of life. LS means was calculated using the ANCOVA model with geographic region, duration of current episode at Baseline (\<4 years vs. ≥ 4years), treatment group, and baseline value as fixed factors.

    Time frame: Baseline, Week 36

  11. Change From Baseline in Skindex-16 AA Functioning Domain Score at Week 36

    Skindex-16 AA was adapted from Skindex-16 for use among adults with alopecia areata. It examines the degree to which the participant is bothered by alopecia (hair loss) and associated symptoms. It is composed of 16 items grouped under 3 domains: Symptoms (4 items), Emotions (7 items), and Functioning (5 items). The score of each item ranges from 0 (never bothered) to 6 (always bothered). Symptoms domain score is sum of 4 items, range 0 to 24; Emotions domain score is sum of 7 items, range 0 to 42; Functioning score is sum of 5 items, range 0 to 30. Higher scores indicate a greater impact on quality of life. LS means was calculated using the ANCOVA model with geographic region, duration of current episode at Baseline (\<4 years vs. ≥ 4years), treatment group, and baseline value as fixed factors.

    Time frame: Baseline, Week 36

  12. Mean Change From Baseline in Hospital Anxiety Depression Scale (HADS) Anxiety Score at Week 36

    The HADS is a 14-item self-assessment scale that determines the levels of anxiety and depression that a patient is experiencing over the past week. The HADS utilizes a 4-point Likert scale (for example, 0 to 3) for each question and is intended for ages 12 to 65 years. Scores for each domain (anxiety and depression) can range from 0 to 21, with higher scores indicating greater anxiety or depression. LS mean was calculated using an ANCOVA model which includes geographic region, duration of current episode at baseline (\<4 years vs. ≥4 years), treatment group and baseline score as fixed factors.

    Time frame: Baseline, Week 36

  13. Mean Change From Baseline in HADS Depression Score at Week 36

    The HADS is a 14-item self-assessment scale that determines the levels of anxiety and depression that a patient is experiencing over the past week. The HADS utilizes a 4-point Likert scale (for example, 0 to 3) for each question and is intended for ages 12 to 65 years. Scores for each domain (anxiety and depression) can range from 0 to 21, with higher scores indicating greater anxiety or depression. LS mean was calculated using an ANCOVA model which includes geographic region, duration of current episode at baseline (\<4 years vs. ≥4 years), treatment group and baseline score as fixed factors.

    Time frame: Baseline,Week 36

07

Results

Posted May 14, 2024

Participant flow

Period 1 (Week 0 to Week 52)
Participant flow — Period 1 (Week 0 to Week 52)
MilestonePlacebo2 mg Baricitinib4 mg BaricitinibPlacebo/ PlaceboPlacebo/ 2-mg BaricitinibPlacebo/ 4-mg Baricitinib2-mg Baricitinib/ 2-mg Baricitinib2-mg Baricitinib/ 4-mg Baricitinib4-mg Baricitinib/ Placebo4-mg Baricitinib/ 2-mg Baricitinib4-mg Baricitinib/ 4-mg Baricitinib
Started17317425900000000
Safety population17117325800000000
Extended safety population14717325800000000
Completed14215123300000000
Not completed31232600000000
Withdrew: Adverse event65600000000
Withdrew: Lack of efficacy51400000000
Withdrew: Lost to follow-up56300000000
Withdrew: Physician decision11000000000
Withdrew: Pregnancy30000000000
Withdrew: Withdrawal by subject891200000000
Withdrew: Met exclusion criteria01100000000
Withdrew: Lack of adherence10000000000
Withdrew: Protocol deviation10000000000
Withdrew: Randomized by mistake and were not dosed10000000000
Period 2 (Week 52 to Week 248)
Participant flow — Period 2 (Week 52 to Week 248)
MilestonePlacebo2 mg Baricitinib4 mg BaricitinibPlacebo/ PlaceboPlacebo/ 2-mg BaricitinibPlacebo/ 4-mg Baricitinib2-mg Baricitinib/ 2-mg Baricitinib2-mg Baricitinib/ 4-mg Baricitinib4-mg Baricitinib/ Placebo4-mg Baricitinib/ 2-mg Baricitinib4-mg Baricitinib/ 4-mg Baricitinib
Started00042691121067647110
Completed0004033503163060
Not completed00002366275701750
Withdrew: Adverse event00000041135
Withdrew: Lack of efficacy0000181161703
Withdrew: Withdrawal by subject0000010202161027
Withdrew: Lost to follow-up00000146215
Withdrew: Study terminated by sponsor00000131123
Withdrew: Physician decision00000110011
Withdrew: Pregnancy00000000001
Withdrew: Protocol defined discontinuation criteria met at week 76000011419404305
Withdrew: Lack of adherence00000100000

Outcome measures

PrimaryPercentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20

The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 202.6 (1.0 to 6.4)17.3 (12.2 to 24.0)32.5 (26.8 to 38.7)
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = <0.001 · Odds ratio (or): 7.86 · 95% CI 2.79 to 22.17
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = <0.001 · Odds ratio (or): 19.72 · 95% CI 7.30 to 53.30
SecondaryPercent Change From Baseline in SALT Score at Week 36

SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes. Least Squares Mean (LSM) was calculated using analysis of covariance (ANCOVA) with geographic region duration of current episode at baseline (\< 4 years versus ≥4 years), treatment group, and baseline value in the model.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · percentage of change
Percent Change From Baseline in SALT Score at Week 36
percentage of changePlacebo2 mg Baricitinib4 mg Baricitinib
Percent Change From Baseline in SALT Score at Week 36-2.96 ± 2.723-28.21 ± 2.770-47.45 ± 2.229
Statistical analysis
  • Placebo vs 2 mg Baricitinib · ANCOVA · p = <0.001 · Mean difference (final values): -25.25 · 95% CI -32.78 to -17.72
  • Placebo vs 4 mg Baricitinib · ANCOVA · p = <0.001 · Mean difference (final values): -44.49 · 95% CI -51.33 to -37.65
SecondaryPercentage of Participants Achieving 50% Improvement of Severity of Alopecia Tool (SALT50)

SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes. SALT50 indicates at least a 50 % improvement from baseline in the SALT score.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 50% Improvement of Severity of Alopecia Tool (SALT50)
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving 50% Improvement of Severity of Alopecia Tool (SALT50)2.6 (1.0 to 6.4)10.9 (6.9 to 16.8)23.5 (18.5 to 29.3)
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.005 · Odds ratio (or): 4.63 · 95% CI 1.58 to 13.60
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = <0.001 · Odds ratio (or): 12.94 · 95% CI 4.72 to 35.44
SecondaryPercentage of Participants With Patient-Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥2-point Improvement From Baseline Among Participants With a Score of ≥3 at Baseline

PRO is an assessment of the particpant's current extent of scalp involvement. It is comprised of 5 category response options: 0= No missing hair (0% of my scalp is missing hair; I have a full head of hair); 1 = A limited area (1% to 20% of my scalp is missing hair); 2 = A moderate area (21% to 49% of my scalp is missing hair); 3 = A large area (50% to 94% of my scalp is missing hair); and 4 = Nearly all or all (95% to 100% of my scalp is missing hair).

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants With Patient-Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥2-point Improvement From Baseline Among Participants With a Score of ≥3 at Baseline
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants With Patient-Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥2-point Improvement From Baseline Among Participants With a Score of ≥3 at Baseline4.0 (1.8 to 8.4)16.1 (11.1 to 22.8)34.4 (28.4 to 41.0)
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.001 · Odds ratio (or): 4.36 · 95% CI 1.77 to 10.74
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = <0.001 · Odds ratio (or): 13.37 · 95% CI 5.75 to 31.10
SecondaryTime for Participants to Achieve SALT ≤ 20 at Week 36.

The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes. Kaplan-Meier method was used for analysis. Time for participants to achieve salt ≤ 20 at week 36 were reported in this outcome measure.

Time frame:
Week 36
Reported as:
Median · Days
Time for Participants to Achieve SALT ≤ 20 at Week 36.
DaysPlacebo2 mg Baricitinib4 mg Baricitinib
Time for Participants to Achieve SALT ≤ 20 at Week 36.NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants Achieving Clinician-Reported Outcome (ClinRO) Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥2 at Baseline)

ClinRO is a clinician reported assessment which measures a participant's EB hair loss. It is comprised of 4 category response options: 0 = EB have full coverage and no areas of hair loss; 1 = There are minimal gaps in EB hair and distribution is even; 2 = There are significant gaps in EB hair or distribution is not even; 3 = No notable EB.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinician-Reported Outcome (ClinRO) Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥2 at Baseline)
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving Clinician-Reported Outcome (ClinRO) Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥2 at Baseline)4.5 (1.9 to 10.0)11.5 (6.7 to 19.1)34.8 (27.9 to 42.4)
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.076 · Odds ratio (or): 2.56 · 95% CI 0.91 to 7.24
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = <0.001 · Odds ratio (or): 10.30 · 95% CI 4.12 to 25.77
SecondaryPercentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥2 at Baseline)

ClinRO measure for EL hair loss is comprised of 4 category response options: 0 = The EL form a continuous line along the eyelids on both eyes; 1 = There are minimal gaps and the EL are evenly spaced along the eyelids on both eyes; 2 = There are significant gaps along the eyelids or the EL are not evenly spaced along the eyelids; 3 = No notable EL.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥2 at Baseline)
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥2 at Baseline)5.6 (2.4 to 12.4)10.1 (5.4 to 18.1)34.3 (26.9 to 42.5)
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.260 · Odds ratio (or): 1.88 · 95% CI 0.63 to 5.62
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = <0.001 · Odds ratio (or): 8.10 · 95% CI 3.18 to 20.66
SecondaryPercentage of Participants Achieving Patient-Reported Outcome (PRO) Measure for EB 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With PRO Measure for EB ≥2 at Baseline)

PRO is an assessment of the participant's current appearance of eyebrows. It is comprised of 4 category response options: 0 = I have full EB on each eye; 1= I have a minimal gap(s) or a minimal amount of thinning in at least 1 of my EB; 2 = I have a large gap(s) or a large amount of thinning in at least 1 of my EB; and 3 = I have no or barely any EB hairs.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Patient-Reported Outcome (PRO) Measure for EB 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With PRO Measure for EB ≥2 at Baseline)
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving Patient-Reported Outcome (PRO) Measure for EB 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With PRO Measure for EB ≥2 at Baseline)4.7 (2.0 to 10.5)14.8 (9.3 to 22.7)35.8 (28.8 to 43.3)
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.017 · Odds ratio (or): 3.43 · 95% CI 1.25 to 9.40
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = <0.001 · Odds ratio (or): 10.85 · 95% CI 4.32 to 27.25
SecondaryPercentage of Participants Achieving PRO Measure for EL 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With PRO Measure EL ≥2 at Baseline)

PRO assessment of the participant's current appearance of EL. It is comprised of 4 category response options: 0 = I have full EL on each eyelid; 1 = I have a minimal gap or minimal gaps along the eyelids; 2 = I have a large gap or large gaps along the eyelids; and 3 = I have no or barely any EL hair.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PRO Measure for EL 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With PRO Measure EL ≥2 at Baseline)
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving PRO Measure for EL 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With PRO Measure EL ≥2 at Baseline)1.1 (0.2 to 6.1)18.9 (12.1 to 28.2)34.6 (27.0 to 43.0)
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.002 · Odds ratio (or): 14.63 · 95% CI 2.73 to 78.42
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = <0.001 · Odds ratio (or): 30.37 · 95% CI 5.93 to 99.99
SecondaryChange From Baseline in Skindex-16 Alopecia Areata (AA) Symptoms Domain Score

Skindex-16 AA was adapted from Skindex-16 for use among adults with alopecia areata. It examines the degree to which the participant is bothered by alopecia (hair loss) and associated symptoms. It is composed of 16 items grouped under 3 domains: Symptoms (4 items), Emotions (7 items), and Functioning (5 items). The score of each item ranges from 0 (never bothered) to 6 (always bothered). Symptoms domain score is sum of 4 items, range 0 to 24; Emotions domain score is sum of 7 items, range 0 to 42; Functioning score is sum of 5 items, range 0 to 30. Higher scores indicate a greater impact on quality of life. LS means was calculated using the ANCOVA model with geographic region, duration of current episode at Baseline (\<4 years vs. ≥ 4years), treatment group, and baseline value as fixed factors.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · score on a scale
Change From Baseline in Skindex-16 Alopecia Areata (AA) Symptoms Domain Score
score on a scalePlacebo2 mg Baricitinib4 mg Baricitinib
Change From Baseline in Skindex-16 Alopecia Areata (AA) Symptoms Domain Score1.17 ± 1.415-1.85 ± 1.425-3.04 ± 1.138
Statistical analysis
  • Placebo vs 2 mg Baricitinib · ANCOVA · p = 0.129 · Mean difference (final values): -3.02 · 95% CI -6.91 to 0.88
  • Placebo vs 4 mg Baricitinib · ANCOVA · p = 0.020 · Mean difference (final values): -4.21 · 95% CI -7.75 to -0.68
SecondaryChange From Baseline in Skindex-16 AA Emotions Domain Score at Week 36

Skindex-16 AA was adapted from Skindex-16 for use among adults with alopecia areata. It examines the degree to which the participant is bothered by alopecia (hair loss) and associated symptoms. It is composed of 16 items grouped under 3 domains: Symptoms (4 items), Emotions (7 items), and Functioning (5 items). The score of each item ranges from 0 (never bothered) to 6 (always bothered). Symptoms domain score is sum of 4 items, range 0 to 24; Emotions domain score is sum of 7 items, range 0 to 42; Functioning score is sum of 5 items, range 0 to 30. Higher scores indicate a greater impact on quality of life. LS means was calculated using the ANCOVA model with geographic region, duration of current episode at Baseline (\<4 years vs. ≥ 4years), treatment group, and baseline value as fixed factors.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · score on a scale
Change From Baseline in Skindex-16 AA Emotions Domain Score at Week 36
score on a scalePlacebo2 mg Baricitinib4 mg Baricitinib
Change From Baseline in Skindex-16 AA Emotions Domain Score at Week 36-11.98 ± 2.154-18.73 ± 2.171-25.40 ± 1.732
Statistical analysis
  • Placebo vs 2 mg Baricitinib · ANCOVA · p = 0.026 · Mean difference (final values): -6.75 · 95% CI -12.68 to -0.82
  • Placebo vs 4 mg Baricitinib · ANCOVA · p = <0.001 · Mean difference (final values): -13.42 · 95% CI -18.80 to -8.04
SecondaryChange From Baseline in Skindex-16 AA Functioning Domain Score at Week 36

Skindex-16 AA was adapted from Skindex-16 for use among adults with alopecia areata. It examines the degree to which the participant is bothered by alopecia (hair loss) and associated symptoms. It is composed of 16 items grouped under 3 domains: Symptoms (4 items), Emotions (7 items), and Functioning (5 items). The score of each item ranges from 0 (never bothered) to 6 (always bothered). Symptoms domain score is sum of 4 items, range 0 to 24; Emotions domain score is sum of 7 items, range 0 to 42; Functioning score is sum of 5 items, range 0 to 30. Higher scores indicate a greater impact on quality of life. LS means was calculated using the ANCOVA model with geographic region, duration of current episode at Baseline (\<4 years vs. ≥ 4years), treatment group, and baseline value as fixed factors.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · score on a scale
Change From Baseline in Skindex-16 AA Functioning Domain Score at Week 36
score on a scalePlacebo2 mg Baricitinib4 mg Baricitinib
Change From Baseline in Skindex-16 AA Functioning Domain Score at Week 36-9.67 ± 1.913-14.05 ± 1.925-18.00 ± 1.535
Statistical analysis
  • Placebo vs 2 mg Baricitinib · ANCOVA · p = 0.103 · Mean difference (final values): -4.38 · 95% CI -9.65 to 0.88
  • Placebo vs 4 mg Baricitinib · ANCOVA · p = <0.001 · Mean difference (final values): -8.33 · 95% CI -13.10 to -3.56
SecondaryMean Change From Baseline in Hospital Anxiety Depression Scale (HADS) Anxiety Score at Week 36

The HADS is a 14-item self-assessment scale that determines the levels of anxiety and depression that a patient is experiencing over the past week. The HADS utilizes a 4-point Likert scale (for example, 0 to 3) for each question and is intended for ages 12 to 65 years. Scores for each domain (anxiety and depression) can range from 0 to 21, with higher scores indicating greater anxiety or depression. LS mean was calculated using an ANCOVA model which includes geographic region, duration of current episode at baseline (\<4 years vs. ≥4 years), treatment group and baseline score as fixed factors.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in Hospital Anxiety Depression Scale (HADS) Anxiety Score at Week 36
score on a scalePlacebo2 mg Baricitinib4 mg Baricitinib
Mean Change From Baseline in Hospital Anxiety Depression Scale (HADS) Anxiety Score at Week 36-0.47 ± 0.225-0.67 ± 0.227-1.19 ± 0.181
Statistical analysis
  • Placebo vs 2 mg Baricitinib · ANCOVA · p = 0.518 · Mean difference (final values): -0.20 · 95% CI -0.82 to 0.42
  • Placebo vs 4 mg Baricitinib · ANCOVA · p = 0.012 · Mean difference (final values): -0.72 · 95% CI -1.28 to -0.16
SecondaryMean Change From Baseline in HADS Depression Score at Week 36

The HADS is a 14-item self-assessment scale that determines the levels of anxiety and depression that a patient is experiencing over the past week. The HADS utilizes a 4-point Likert scale (for example, 0 to 3) for each question and is intended for ages 12 to 65 years. Scores for each domain (anxiety and depression) can range from 0 to 21, with higher scores indicating greater anxiety or depression. LS mean was calculated using an ANCOVA model which includes geographic region, duration of current episode at baseline (\<4 years vs. ≥4 years), treatment group and baseline score as fixed factors.

Time frame:
Baseline,Week 36
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in HADS Depression Score at Week 36
score on a scalePlacebo2 mg Baricitinib4 mg Baricitinib
Mean Change From Baseline in HADS Depression Score at Week 360.29 ± 0.208-0.22 ± 0.210-0.39 ± 0.167
Statistical analysis
  • Placebo vs 2 mg Baricitinib · ANCOVA · p = 0.083 · Mean difference (final values): -0.51 · 95% CI -1.08 to 0.07
  • Placebo vs 4 mg Baricitinib · ANCOVA · p = 0.010 · Mean difference (final values): -0.68 · 95% CI -1.20 to -0.16

Adverse events

Collected over Baseline up to end of follow up (up to 252 weeks). (AE Description: As pre-specified in the SAP, AE were assessed using the "safety population". Given the sequential dose change within Period 2 (Week 52 to Week 248) it was not appropriate to attribute AEs to a single fixed dose, and therefore AEs were not collected separately).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/171 (0%)3/171 (1.8%)44/171 (25.7%)
2 mg Baricitinib0/173 (0%)5/173 (2.9%)85/173 (49.1%)
4 mg Baricitinib0/258 (0%)16/258 (6.2%)133/258 (51.6%)
All Baricitinib- Extended0/578 (0%)34/578 (5.9%)321/578 (55.5%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventPlacebo2 mg Baricitinib4 mg BaricitinibAll Baricitinib- Extended
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/640/630/970/215
VaricoceleReproductive system and breast disorders0/640/631/971/215
AdenomyosisReproductive system and breast disorders0/1071/1100/1611/363
Cholecystitis acuteHepatobiliary disorders1/1711/1732/2583/578
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1070/1101/1611/363
Strangulated umbilical herniaGastrointestinal disorders1/1710/1730/2580/578
Cardiac failure congestiveCardiac disorders0/1711/1730/2581/578
Covid-19 pneumoniaInfections and infestations0/1711/1730/2583/578
PyelonephritisInfections and infestations0/1711/1731/2582/578
Ankle fractureInjury, poisoning and procedural complications0/1711/1730/2582/578
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlacebo2 mg Baricitinib4 mg BaricitinibAll Baricitinib- Extended
Covid-19Infections and infestations1/17118/17345/258148/578
Upper respiratory tract infectionInfections and infestations13/17124/17331/25877/578
HeadacheNervous system disorders10/17117/17335/25874/578
NasopharyngitisInfections and infestations8/1719/17330/25854/578
Urinary tract infectionInfections and infestations4/17118/17320/25860/578
AcneSkin and subcutaneous tissue disorders3/17111/17316/25840/578
Blood creatine phosphokinase increasedInvestigations1/1713/17317/25832/578
CoughRespiratory, thoracic and mediastinal disorders5/1714/17314/25831/578
HypercholesterolaemiaMetabolism and nutrition disorders2/1718/17310/25831/578
Weight increasedInvestigations1/1719/1733/25819/578

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Placebo2 mg Baricitinib4 mg BaricitinibTotal
Mean36.0 ± 12.2438.2 ± 12.9637.2 ± 12.4737.2 ± 12.55
Sex: Female, Male
Sex: Female, Male(Participants)Placebo2 mg Baricitinib4 mg BaricitinibTotal
Female108111161380
Male656398226
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo2 mg Baricitinib4 mg BaricitinibTotal
American Indian or Alaska Native0000
Asian686792227
Native Hawaiian or Other Pacific Islander0101
Black or African American16121846
White8592144321
More than one race42511
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Placebo2 mg Baricitinib4 mg BaricitinibTotal
Argentina15112046
Australia17172054
Brazil14132451
China19203170
Israel14192558
Japan10112041
South Korea23172666
Taiwan7121130
United States545482190
Baseline Disease Severity of Alopecia Tool (SALT) Score
Baseline Disease Severity of Alopecia Tool (SALT) Score(units on a scale)Placebo2 mg Baricitinib4 mg BaricitinibTotal
Mean84.6 ± 17.7585.3 ± 18.3084.9 ± 18.0385.0 ± 18.00
08

Study locations

96 sites
  • Total Skin and Beauty Dermatology Center, PC
    Birmingham, Alabama 35205, United States
  • Investigate MD
    Scottsdale, Arizona 85255, United States
  • Center For Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
  • Quest Dermatology Research
    Northridge, California 91324, United States
  • Kaiser Permanente Hospital
    San Francisco, California 94118, United States
  • New England Research Associates
    Bridgeport, Connecticut 06606, United States
  • Florida Academic Centers Research and Education, LLC
    Coral Gables, Florida 33134, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • ForCare Clinical Research
    Tampa, Florida 33613-1244, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • The South Bend Clinic Center for Research
    South Bend, Indiana 46617, United States
  • Qualmedica Research, LLC
    Owensboro, Kentucky 42303, United States
  • Dermatology and Skin Cancer Specialists
    Rockville, Maryland 20850, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Great Lakes Research Group, Inc.
    Bay City, Michigan 48706, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Hamzavi Dermatology
    Fort Gratiot, Michigan 48059, United States
  • Associated Skin Care Specialists
    New Brighton, Minnesota 55112, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
  • Joseph J. Schwartz, M.D.
    Troy, New York 12180, United States
  • The University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27516, United States
  • Dermatology Specialists of Charlotte
    Charlotte, North Carolina 28211, United States
  • M3-Emerging Medical Research
    Raleigh, North Carolina 27612, United States
  • Bexley Dermatology Research
    Bexley, Ohio 43209, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Dermatologists of Southwest Ohio
    Mason, Ohio 45040, United States
  • Vital Prospects Clinical Research Institute, P.C.
    Tulsa, Oklahoma 74136, United States
  • Northwest Dermatology Institute
    Portland, Oregon 97210, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Velocity Clinical Research, Providence
    East Greenwich, Rhode Island 02818, United States
  • Suzanne Bruce and Associates, PA
    Houston, Texas 77056, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
  • Virginia Clinical Research, Inc.
    Norfolk, Virginia 23502, United States
  • Stat Research
    CABA, Buenos Aires C1023AAB, Argentina
  • Instituto de Neumonología y Dermatología
    Capital Federal, Buenos Aires 1425, Argentina
  • Centro de Investigaciones Metabólicas (CINME)
    Ciudad Autónoma de Buenos Aires, Buenos Aires 1027, Argentina
  • Buenos Aires Skin
    Buenos Aires, Buenos Aires F.D. 1055, Argentina
  • Fundacion Respirar
    Buenos Aires, Ciudad Autonoma Buenos Aires C1426ABO, Argentina
  • Centro de Investigaciones Médicas Tucuman
    SAN M. de Tucuman, Tucumán Province T4000AXL, Argentina
  • Parra Dermatología
    Mendoza, 5500, Argentina
  • Woden Dermatology
    Phillip, Australian Capital Territory 2606, Australia
  • Skin & Cancer Foundation Australia
    Westmead, New South Wales 2045, Australia
  • Veracity Clinical Research Pty Ltd
    Woolloongabba, Queensland 4102, Australia
  • Clinical Trials SA Pty Ltd
    Campbelltown, South Australia 5073, Australia
  • Skin Health Institute Inc.
    Carlton, Victoria 3053, Australia
  • Sinclair Dermatology
    Melbourne, Victoria 3002, Australia
  • Fremantle Dermatology
    Fremantle, Western Australia 6160, Australia
  • IDERJ - Instituto de Dermatologia e Estética do Brasil
    Rio de Janeiro, Rio de Janeiro 22470-220, Brazil
  • Irmandade da Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90050-170, Brazil
  • Centro de Pesquisa Sao Lucas
    Campinas, São Paulo 13034-685, Brazil
  • Hospital de Clínicas Da Universidade Estadual de Campinas
    Campinas, São Paulo 13083-888, Brazil
  • Faculdade de Medicina do ABC
    Santo André, São Paulo 09060-870, Brazil
  • IBPClin - Instituto Brasil de Pesquisa Clínica
    Rio de Janeiro, 22241-180, Brazil
  • IPITEC
    São Paulo, 01223-001, Brazil
  • Servidor Público Estadual - IAMSPE - centro de estudos urológicos
    São Paulo, 04039-901, Brazil
  • Beijing Chao-Yang Hospital, Capital Medical University
    Beijing, Beijing Municipality 100020, China
  • Beijing Friendship Hospital Affiliate of Capital University
    Beijing, Beijing Municipality 100050, China
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
  • Chinese PLA General Hospital
    Beijing, Beijing Municipality 100853, China
  • Guangdong Province Dermatology Hospital
    Guangzhou, Guangdong 510018, China
  • Xiangya Hospital Central South University
    Changsha, Hunan 410008, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212000, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710004, China
  • HuaShan Hospital Affiliated To Fudan University
    Shanghai, Shanghai Municipality 200040, China
  • Shanghai Skin Disease Hospital
    Shanghai, Shanghai Municipality 200071, China
  • First Affiliated Hospital of Shanxi Medical University
    Taiyuan, Shanxi 30001, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality 300052, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang 310014, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310052, China
  • Rabin Medical Center
    Petah Tikva, Central District 4941492, Israel
  • Sheba Medical Center
    Ramat Gan, Central District 5262100, Israel
  • Hadassah Medical Center
    Jerusalem, Jerusalem 9112001, Israel
  • Emek Medical Center
    Afula, Northern District 1834111, Israel
  • Rambam Medical Center
    Haifa, Northern District 3109601, Israel
  • Soroka Medical Center
    Beersheba, Southern District 8410101, Israel
  • Sourasky Medical Center
    Tel Aviv, Tell Abīb 6423906, Israel
  • Yokohama Rosai Hospital
    Yokohama, Kanagawa 222-0036, Japan
  • Hamamatsu University Hospital
    Hamamatsu, Shizuoka 431-3192, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo 113-8431, Japan
  • Juntendo Tokyo Koto Geriatric Medical Center
    Koto-ku, Tokyo 136-0075, Japan
  • Kyorin University Hospital
    Mitaka, Tokyo 181-8611, Japan
  • Tokyo Medical Univ. Hospital
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Yamaguchi University Hospital
    Ube, Yamaguchi 755-8505, Japan
  • Osaka City University Hospital
    Osaka, 545-8586, Japan
  • Clinical Research Puerto Rico
    San Juan, 00909, Puerto Rico
  • Dankook University Hospital
    Cheonan, Chungcheongnam-do 31116, South Korea
  • Soonchunhyang University Bucheon Hospital
    Bucheon-si, Gyeonggi-do 14584, South Korea
  • Ajou University Hospital
    Suwon, Gyeonggi-do 16499, South Korea
  • Boramae Medical Center
    Dongjak-gu, Seoul-teukbyeolsi [Seoul] 07061, South Korea
  • Kyunghee University Hospital at Gangdong
    Seoul, Seoul-teukbyeolsi [Seoul] 134-090, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
  • Chung Shan Medical University Hospital
    Taichung, Taichung 402, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Chang Gung Medical Foundation-Linkou Branch
    Taoyuan, 333, Taiwan
09

References and documents

Publications

  • King B, Mostaghimi A, Shimomura Y, Piraccini BM, Blume-Peytavi U, Sontag A, Dutronc Y, Denning K, Kolodsick J, Lu X, Srivastava A, Sinclair R. Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment. Am J Clin Dermatol. 2025 Jul;26(4):611-622. doi: 10.1007/s40257-025-00932-0. Epub 2025 Apr 11. PubMed 40214720 ↗
  • Craiglow B, Lee YW, Vano-Galvan S, Egeberg A, Dutronc Y, Durand F, Pierce E, Yu G, Chen YF, Mostaghimi A. Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib. Dermatol Ther (Heidelb). 2024 Jul;14(7):1959-1968. doi: 10.1007/s13555-024-01208-x. Epub 2024 Jun 21. PubMed 38904749 ↗
  • Senna MM, Kwon O, Piraccini BM, Sinclair R, Ball S, Ding Y, Chen YF, Dutronc Y, King B. Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata. Dermatol Ther (Heidelb). 2023 Dec;13(12):3209-3220. doi: 10.1007/s13555-023-01063-2. Epub 2023 Nov 22. PubMed 37991697 ↗
  • Ko JM, Mayo TT, Bergfeld WF, Dutronc Y, Yu G, Ball SG, Somani N, Craiglow BG. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials. JAMA Dermatol. 2023 Sep 1;159(9):970-976. doi: 10.1001/jamadermatol.2023.2581. PubMed 37556146 ↗
  • Piraccini BM, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen YF, Dutronc Y, Pierce E, Durand F, Mostaghimi A. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials. J Dermatolog Treat. 2023 Dec;34(1):2227299. doi: 10.1080/09546634.2023.2227299. PubMed 37381691 ↗
  • Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, Yu G, Chiasserini C, McCollam J, Wu WS, King B. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023 May;24(3):443-451. doi: 10.1007/s40257-023-00764-w. Epub 2023 Mar 1. PubMed 36855020 ↗
  • King B, Mostaghimi A, Shimomura Y, Zlotogorski A, Choi GS, Blume-Peytavi U, Passeron T, Holzwarth K, Dutronc Y, McCollam J, Yang FE, Stanley S, Wu WS, Sinclair R. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2023 Feb 10;188(2):218-227. doi: 10.1093/bjd/ljac059. PubMed 36763878 ↗
  • King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. PubMed 35334197 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Jan 2021, 18 months.

Results were first posted in May 2024, 3 years 3 months after primary completion. A results delay was requested in Jan 2022.

Of 20 phase 3 interventional studies under Alopecia Areata, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2019
First posted
Apr 2, 2019
StartActual
Jul 8, 2019
Primary completionActual
Jan 24, 2021
CompletionActual
Nov 19, 2024
Results delay requested
Jan 24, 2022
Results first posted
May 14, 2024
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03899259
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Apr 2, 2019
Start date
Jul 8, 2019
Primary completion
Jan 24, 2021
Completion
Nov 19, 2024
Results posted
May 14, 2024
Last update
Apr 7, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM -5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion